Rising prevalence of Dupuytren's disease globally, aging population, and increasing awareness about advanced treatment options are key growth drivers for the market.
Technological advancements leading to the development of novel therapies and increasing investment in research and development activities are expected to further drive market growth.
Growing adoption of minimally invasive procedures and favorable reimbursement policies are also contributing to the expansion of the Dupuytren's disease market.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Disease Type, Type, End-Use |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Bayer AG, Novartis AG, Pfizer, Nantong Jinghua Pharmaceutical, Actiza Pharmaceutical Pvt.., Endo International Plc, Bristol-Meyers Squibb Company, Spear Pharmaceuticals, GSK Plc., AstraZeneca, Hikma Pharmaceuticals Plc, LEO Pharma A/S, Fresenius Kabi AG |
High cost of treatment and limited availability of effective therapies are major restraints for the Dupuytren's disease market.
Lack of skilled healthcare professionals and challenges related to post-operative care and rehabilitation further hinder market growth.